Project Grant R34DA062543
- This Project Grant award of $1,573,958 from the National Institute on Drug Abuse (NIDA), part of the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on identifying individuals who are viremic and/or have substance use disorder (SUD) to engage them for early intervention. The project will implement routine SUD screening using the NIDA Quick Screen and a social network intervention to find individuals who are viremic, have SUD, or both, and link them to harm reduction and HIV...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $381,487 to the University of Maryland, Baltimore (UMB) to assess the early implementation of long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) among adolescent girls and young women (AGYW) at high risk of HIV acquisition in Zambia. The key objectives are to: 1) Evaluate implementation determinants of CAB-LA...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $677,250 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Miami. The grant, awarded on June 15, 2025, supports the development and testing of the "Healthcare Empowerment and Advocacy for Recovery from Trafficking (HEART) Intervention" for implementation in syringe service programs. The project aims to engage women with experiences of...
- This Project Grant award of $2,332,500.00 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to transform systems of care in Washington state prisons to better address HIV, HIV risk, and substance use disorders. The key products and services to be delivered include: Building the foundation for a "prison learning health system" to improve the quality, efficiency, and reach of HIV treatment, HIV prevention, and...
- This federal Project Grant award of $182,249, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the implementation and evaluation of a digitally enhanced intervention called EMPWR (Empowering Pregnant Women Receiving Medications for Opioid Use Disorder). The primary objectives of this grant are to: (1) Evaluate the feasibility of implementing the EMPWR intervention, which is designed to improve retention of pregnant...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $426,036 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Tulane University. The award will fund a study to examine the feasibility and acceptability of a virtual reality-based mindfulness intervention, called "TRIPP," to support people with comorbid HIV and substance use disorders. This population faces significant public health challenges, as substance...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $4,725,000 to the University of California, Los Angeles (UCLA) to develop new dissemination strategies that improve the availability and user-friendliness of research on preventing HIV transmission and effectively treating substance use disorders (SUDs). The project aims to mitigate policy-level barriers and upstream barriers that hinder access...
- The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $687,416 Project Grant to the J. David Gladstone Institutes in San Francisco, California. The grant is for a research project titled "Targeted Small Molecule Recruitment to Suppress the HIV Transcriptionally Active Reservoir" and runs from May 15, 2025 to March 31, 2030. The key objectives of this research project are to develop therapeutically effective...
- This Project Grant award, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to investigate the effects of opioids on HIV transcription and latency. The $234,000 award to Georgetown University will support research using a novel dual fluorescent and bioluminescent virus called EcoHIV NL4-3 Dual Red to visualize active HIV proviral transcription in microglia and astrocytes. The study will examine the mechanisms by which...
- This $375,000 federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) aims to evaluate the impact of a status-neutral, person-centric intervention called the "Blue Shed" on HIV transmission and outcomes among people who inject drugs (PWID) in New Delhi, India. The project has three key objectives: Assess the direct impact of the Blue Shed intervention on HIV incidence, viral suppression, and mortality among PWID...
This federal Project Grant award, titled "Integrated Services for PWID Using Person-Centered Interactions, Reach, and Engagement (INSPIRE)", is funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The University of Maryland, Baltimore was awarded $219,291 on September 30, 2025 to co-adapt and evaluate an HIV status-neutral collaborative care management model for HIV prevention, HIV care, mental health, and medication for opioid use disorder (MOUD) services targeting people who inject drugs (PWID) in Zambia. The key objectives are to: 1) Assess the multilevel determinants of early MOUD implementation, 2) Co-adapt an integrated, person-centered collaborative care model with stakeholders, and 3) Pilot test the co-adapted model's implementation, feasibility, and preliminary effectiveness within the Zambian health system. This implementation science study aims to address major gaps in the HIV epidemic response among PWID in Zambia and develop evidence-based approaches for integrating MOUD with HIV services.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $34.6k | 9/18/25 | ||
| Not listed | $184.7k | 9/16/25 |